Given limited suppressive activity of limonene in the initiation phase of NMU-induced mammary carcinogenesis, Chander et al. assessed if supplementation with a aromatase inhibitor (4- hydroxyandrostenedione) could enhance tumor inhibition [33]. This evidence concerns the gene CYP19A1 and neoplasm.